Vascular Biogenics Ltd expected to post a loss of 11 cents a share - Earnings Preview

Notable Labs

11/11/2022 17:06

* Vascular Biogenics Ltd  VBLT.OQ   VBLT.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
14 (estimated). 
    * The Or Yehuda Israel-based   company is expected to report
 a
0.5% increase in revenue to $200 thousand from $199 thousand a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vascular Biogenics
Ltd is
for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vascular
Biogenics Ltd is $5​, above​ its last closing price of $0.12.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.11       -0.10      -0.12     Missed  -14.3
 Mar. 31 2022  -0.11       -0.11      -0.13     Missed  -20.4
 Dec. 31 2021  -0.08       -0.09      -0.12     Missed  -37.1​
 Sep. 30 2021  -0.11       -0.11      -0.09     Beat    16.3
 ​​Jun.        -0.11       -0.11      -0.12     Missed  -11.6
 30 2021                                                
 Mar. 31 2021  -0.13       -0.13      -0.12     Beat    7.7​
 Dec. 31 2020              -0.14      -0.15     Missed  -7.1
 Sep. 30 2020  -0.14       -0.13      -0.12     Beat    10.2
 This summary was machine generated November 11 at 17:06 GMT. 
All figures in US dollars  unless otherwise stated